drug · small molecule
sirolimus
Phase 3updated 6mo agoby OrphAI Therapeutics Inc🔗 ChEMBL
Phase 3community read0 votes
🐶 often sniffed alongside
top 3Small molecule drug with a maximum clinical stage of Approval (across all indications), with 19 approved and 113 investigational indications.
targets
Peptidyl-prolyl cis-trans isomerase FKBP1A
all catalysts(0)
nothing on the calendar yet
Trials studying sirolimus
- phase1A Phase 1 Study of UB-VV500 With Rapamycin in Relapsed/Refractory Multiple Myeloma
- phase2A Phase 1/2 Study of UB-VV400 With Rapamycin in Relapsed/Refractory B-cell Malignancies
- N/ASafety and Effectiveness of the Orsiro Mission 48-mm Sirolimus Eluting Coronary Stent System in Subjects With Coronary Artery Lesions
- N/AVirtue® SAB in the Treatment of Coronary ISR Trial
- N/AIVUS-Guided Sirolimus-Coated Balloon Versus Sirolimus-Eluting Stent for De Novo Large Vessel Lesions in ACS
- phase2A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis
- phase2Phase 1/2a Clinical Trial of PR001 (LY3884961) in Patients With Parkinson's Disease With at Least One GBA1 Mutation (PROPEL)
- phase2Study of ASP2957 in Male Participants With X-linked Myotubular Myopathy Who Need Ventilators
News(4)
- Cordis’ sirolimus drug-coated balloon earns FDA approval as a breakthrough deviceThe FDA gave the green light to a first and only sirolimus drug-eluting balloon designed by Cordis to treat coronary in-stent restenosis.fiercebiotech · 1mo ago
- Opinion: Limb girdle muscular dystrophy patients face a maddening reality“Too often, regulatory tools authorized to speed patient access to breakthrough treatments are being used in ways that even prevent approval,” writes Kat Bryant Knudson.stat · 3mo ago
- Ipsen’s $450M blood cancer drug; FDA selects first cohort for “pre-check” pilot programThe planned acquisition of Kartos Therapeutics would hand Ipsen a late-stage asset for myelofibrosis. Elsewhere, Sobi hit a regulatory setback and BeOne unveiled more positive Brukinsa data.biopharma_dive · 4mo ago
- STAT+: Drug meant to make gene therapy safer may also make it less effectiveEncoded Therapeutics gives a heads-up to other gene therapy company about the trade-offs with a drug meant to improve safety.stat · 6mo ago
Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that